HRP20250591T1 - 5‑[[4‑[2‑[5‑(1‑hidroksietil)piridin‑2‑il]etoksi]fenil]metil]‑1,3‑tiazolidin‑2,4‑dion i njegove soli, namijenjen upotrebi u liječenju mitohondrijskih bolesti - Google Patents

5‑[[4‑[2‑[5‑(1‑hidroksietil)piridin‑2‑il]etoksi]fenil]metil]‑1,3‑tiazolidin‑2,4‑dion i njegove soli, namijenjen upotrebi u liječenju mitohondrijskih bolesti

Info

Publication number
HRP20250591T1
HRP20250591T1 HRP20250591TT HRP20250591T HRP20250591T1 HR P20250591 T1 HRP20250591 T1 HR P20250591T1 HR P20250591T T HRP20250591T T HR P20250591TT HR P20250591 T HRP20250591 T HR P20250591T HR P20250591 T1 HRP20250591 T1 HR P20250591T1
Authority
HR
Croatia
Prior art keywords
compound
use according
thiazolidine
dione
pyridin
Prior art date
Application number
HRP20250591TT
Other languages
English (en)
Croatian (hr)
Inventor
Marc Martinell Pedemonte
Maria Pilar Pizcueta Lalanza
Laura Pilar RODRÍGUEZ PASCAU
Original Assignee
Minoryx Therapeutics S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S.L. filed Critical Minoryx Therapeutics S.L.
Publication of HRP20250591T1 publication Critical patent/HRP20250591T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20250591TT 2018-06-06 2019-06-06 5‑[[4‑[2‑[5‑(1‑hidroksietil)piridin‑2‑il]etoksi]fenil]metil]‑1,3‑tiazolidin‑2,4‑dion i njegove soli, namijenjen upotrebi u liječenju mitohondrijskih bolesti HRP20250591T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382397 2018-06-06
EP19742480.7A EP3801515B1 (en) 2018-06-06 2019-06-06 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
PCT/IB2019/054696 WO2019234664A1 (en) 2018-06-06 2019-06-06 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases

Publications (1)

Publication Number Publication Date
HRP20250591T1 true HRP20250591T1 (hr) 2025-07-04

Family

ID=62716008

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20250591TT HRP20250591T1 (hr) 2018-06-06 2019-06-06 5‑[[4‑[2‑[5‑(1‑hidroksietil)piridin‑2‑il]etoksi]fenil]metil]‑1,3‑tiazolidin‑2,4‑dion i njegove soli, namijenjen upotrebi u liječenju mitohondrijskih bolesti

Country Status (13)

Country Link
US (2) US11957670B2 (enExample)
EP (2) EP3801515B1 (enExample)
JP (1) JP7376934B2 (enExample)
DK (1) DK3801515T3 (enExample)
ES (1) ES3028538T3 (enExample)
FI (1) FI3801515T3 (enExample)
HR (1) HRP20250591T1 (enExample)
HU (1) HUE071482T2 (enExample)
LT (1) LT3801515T (enExample)
PL (1) PL3801515T3 (enExample)
PT (1) PT3801515T (enExample)
SI (1) SI3801515T1 (enExample)
WO (1) WO2019234664A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
CA3127590A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
EP3917509A4 (en) 2019-01-28 2022-11-09 Mitochondria Emotion, Inc. TRANS-4-HYDROXYCYCLOHEXYLPHENYLAMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107362165A (zh) 2011-01-10 2017-11-21 金帆德尔制药股份有限公司 用于治疗阿尔茨海默病的方法和药物产品
EP3013371A4 (en) 2013-06-26 2017-04-26 Rett Syndrome Research Trust Rett syndrome and treatments therefore
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
NZ725492A (en) 2014-04-02 2023-06-30 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
US20180364595A1 (en) 2015-09-30 2018-12-20 Nikon Corporation Exposure apparatus, flat panel display manufacturing method, and device manufacturing method
WO2017083739A1 (en) 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
CN106202285A (zh) 2016-06-30 2016-12-07 北京百度网讯科技有限公司 搜索结果展示方法和装置
MX379710B (es) 2016-12-01 2025-03-11 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-tiazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico.
CN110198945B (zh) 2016-12-23 2023-06-27 米尼奥尔克斯治疗有限公司 用于制备噻唑烷二酮化合物及其盐的方法
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
MX2020013182A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.

Also Published As

Publication number Publication date
WO2019234664A1 (en) 2019-12-12
ES3028538T3 (en) 2025-06-19
JP2021527049A (ja) 2021-10-11
DK3801515T3 (da) 2025-04-28
HUE071482T2 (hu) 2025-08-28
US20210228559A1 (en) 2021-07-29
JP7376934B2 (ja) 2023-11-09
LT3801515T (lt) 2025-06-10
FI3801515T3 (fi) 2025-05-27
PL3801515T3 (pl) 2025-07-14
EP4545142A2 (en) 2025-04-30
EP3801515A1 (en) 2021-04-14
EP4545142A3 (en) 2025-06-11
PT3801515T (pt) 2025-06-11
US11957670B2 (en) 2024-04-16
EP3801515B1 (en) 2025-04-09
SI3801515T1 (sl) 2025-07-31
US20250064791A1 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
HRP20210576T1 (hr) 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dion, namijenjen liječenju nealkoholne masne bolesti jetre
HRP20170352T1 (hr) Spojevi bis(fluroalkil)-1,4-benzodiazepinona kao notch inhibitori
FI3801515T3 (fi) 5-[[4-[2-[5-(1-hydroksietyyli)pyridin-2-yyli]etoksi]fenyyli]metyyli]-1,3-tiatsolidiini-2,4-dionia ja sen suoloja käytettäviksi mitokondriosairauksien hoidossa
JP2006077019A5 (enExample)
JP2020516671A5 (enExample)
JP2017214387A5 (enExample)
JP2013531031A5 (enExample)
HRP20130738T1 (hr) Postupak lijeäśenja ili profilakse
JP2014528464A5 (enExample)
JP2013544276A5 (enExample)
JP2013527243A5 (enExample)
JP2019500387A5 (enExample)
JP2016505619A5 (enExample)
JP2007505933A5 (enExample)
WO2005075468A3 (en) Pyridinyl - or pyrimidinyl thiazoles with protein kinase inhibiting activity
JP2013510825A5 (enExample)
JP2013539789A5 (enExample)
JP2007533740A5 (enExample)
JP2010265321A5 (enExample)
JP2014500265A5 (enExample)
HRP20160450T1 (hr) Novi inhibitori reduktaze s-nitrozoglutationa
RU2015121043A (ru) Производные фенилэтилпиридина в качестве ингибиторов PDE-4
JP2014509647A5 (enExample)
JP2017505293A5 (enExample)
HRP20161797T1 (hr) Spojevi 1,3-oksazolidina ili 1,3-oksazinana kao antagonisti receptora oreksina